Dr. Nathan Karin has served as a professor of Immunology at Technion University since 1995. He is a world leader in the fight against autoimmune diseases such as multiple sclerosis. Dr. Karin investigates the factors that may contribute to the nerve-damaging attacks that occur in MS, and the ways in which the immune system attacks myelin. Dr. Karin's research is also being examined for treatment of cancer through studying the role of chemokines in that disease, particularly with prostate cancer and melanoma.
Dr. Karin attended the Hebrew University of Jerusalem and received a master's degree in Immunology. He then received his doctoral degree in Immunology from the Weizmann Institute and conducted post-doctoral work at Stanford University Medical School from 1990 - 1995. At Stanford, Dr. Karin discovered a major mechanism of cell migration to sites of inflammation that led to the development of one of the leading drugs for MS, named Natalizumab (Tysabri). This drug is manufactured by Biogen-Idec. Presently more than 112,000 patients have received this medication. For his outstanding research, Dr. Karin received a post-doctoral fellowship award from the National MS Society.